: iStockAnalyst.com Symbols Feed

Small Cap, High Growth Healthcare Trio

Wed, 28 Jan 2009 18:16:00 GMT

Jim Oberweis, Jr., money manager and editor of The Oberweis Report, is a long-standing expert in small cap, high growth growth stocks, and focused on those issues trading a reasonable valuations relative to their growth rates. Here, the advisors looks at a trio of specialty healthcare companies involved in niche markets such as women's health, autoimmune disease and vaccines. "The Female Health Company (NYSE: FHC) manufactures and markets the female condom. This product currently is the only medical device approved[More...]

Akorn, Inc. Announces Second Quarter 2009 Earnings Release and Conference Call Information

Thu, 30 Jul 2009 16:52:00 GMT

Akorn, Inc. will release second quarter 2009 earnings Monday, August 10 after stock market close. The company will host a conference call on Tuesday, August 11 to discuss quarterly results followed by a Q&A session:[More...]

Akorn, Inc. Announces Second Quarter 2009 Earnings Release and Conference Call Information

Wed, 29 Jul 2009 15:24:00 GMT

Akorn Acquires Capastat® Sulfate from Eli Lilly and Company

Wed, 17 Jun 2009 13:49:00 GMT

Akorn, Inc. (NASDAQ: AKRX) today announced that it has entered into an agreement to acquire from Eli Lilly and Company (NYSE: LLY) all rights in the U.S. and Canada to manufacture, market and sell the lyophilized antibiotic Capastat® Sulfate (capreomycin for injection, USP). Akorn will own the Capastat NDA and expects to launch the product in the third quarter of this year.[More...]

Akorn Announces Management Changes

Tue, 09 Jun 2009 13:24:00 GMT

Akorn, Inc. (NASDAQ:AKRX) today announced the appointment of Raj Rai as Interim Chief Executive Officer while the Board of Directors conducts a search to find a permanent replacement. Mr. Rai replaces Jeffery A. Whitnell, who is leaving the company to pursue other interests.[More...]

Akorn Reports First Quarter 2009 Financial Results

Tue, 12 May 2009 11:47:00 GMT

Akorn, Inc. (NASDAQ: AKRX) a specialty pharmaceutical company, today reported on financial results for the first quarter ended March 31, 2009.
The revenue increase was driven by higher Td Vaccine sales, which totaled $10.7 million.
During the first quarter 2009, the Company recognized equity earnings totaling $60K from its investment in the Akorn-Strides, LLC joint venture.

[More...]

Akorn Issues Important Business Updates:-- Purchase of Existing Credit Facility ---- Renegotiation of Distribution Agreement --

Wed, 01 Apr 2009 11:01:00 GMT

Akorn, Inc. (NASDAQ: AKRX) today announced that EJ Funds has purchased all of General Electric Capital Corporation’s rights as the lender under Akorn’s Credit Agreement with GE Capital. As of March 31, 2009, the effective date of the purchase, Akorn owed approximately $5.5 million under the Credit Agreement. EJ Funds is affiliated with EJ Financial Enterprises, Inc., whose President is Dr. John N. Kapoor, Akorn’s Chairman and largest shareholder.[More...]

Akorn Appoints Jeffrey A. Whitnell as Interim Chief Executive Officer

Mon, 30 Mar 2009 11:02:00 GMT

Akorn, Inc. (NASDAQ:AKRX) today announced the appointment of Jeffrey A. Whitnell as Interim Chief Executive Officer. Mr. Whitnell will work in this capacity under the oversight of the Special Committee of the Board of Directors until a new CEO is named. As the company has previously announced, the Special Committee was established to oversee the operations of the company while the search for a new CEO is underway.[More...]

Akorn Appoints Raj Rai as Strategic Consultant

Mon, 02 Mar 2009 11:06:00 GMT

Akorn, Inc. (NASDAQ: AKRX) today announced the appointment of Raj Rai as Strategic Consultant to the Special Committee of the Board of Directors. As the company has previously announced, the Special Committee was established following the departure of Arthur Przybyl, formerly President and CEO, to oversee the operations of the company while the search for a new CEO is underway. Mr. Rai will advise the Committee as it evaluates its various business segments and works towards a positive resolution of its working capital needs.[More...]